Member Info for Balerno2

Post on LinkedIn under Wp partners scancell.

With the financial resources to enable significant milestones to be achieved and the early clinical success of scib1, a cd8 cell cancer immunotherapy and modi1, a cd4 DNA vaccine also in trial, this should now take off. In business you need the right people, the money and the luck. All the stars are converging.

If not more as the BOD have dipped into their own pockets. Isn’t that a real sign. We’ve always wanted them to do what we have done. It’s what the city want.

So if you have technology that stimulates CD4 and CD8 cells, surely that has a more generic application and is just looking for a range of targets?

Spot on Burble. My thoughts too.

We have platform technologies therefore they can be quickly adapted for other conditions. Also didn’t we have orphan status for scib1 in the USA some years ago? Plus the work Texas Bio is doing.

The issue will be when does a small cohort go over the deminimus level?

From the Economist but it’s about customised medicine. What is customised medicine and could it bring other scib , modi or glycans to market faster?

The headlines about the autumn statement from Jeremy Hunt, the chancellor, this week focused on tax and spending. But tucked away in the written documents was news that could hone the cutting-edge of medicine. The Medicines and Health-care products Regulatory Agency (mhra) is working with Genomics England, Oxford University and Mila’s Miracle Foundation, a charity, to develop a regulatory pathway to allow one-off drugs to be designed and approved for use in individual patients in less than a year.

Medicines currently travel a well-worn route to market comprising two or three phases of trials in large groups of patients. But this approach is impossible for the vast majority of genetic disorders, which are often vanishingly rare or even unique. The technology to customise medicines for people with such conditions exists but the regulatory route they must take is rocky.

Hi Cleaner,

Well done for posting the twitter feed. Didn’t one slide say RIP individualised therapy?

It’s been very quiet on the Modi front and I suspect something is due at the agm. I can’t make it either but SCIB has been a diversion and a Modi report is due. Plus maybe some progress on commercials too.

Hi Burble

Thank you for your perceptive analysis and comparison. I have been expecting an update on sept info and did not realise the new one was an update. In trying to access the graphs I find that the web links are no longer valid as the data has been with drawn.

Therefore as the overall numbers of patients haven’t

changed, maybe the nomenclature refers to rankings and that is the reason for the differences? However without access it can’t be checked.

So what’s happened to Fosun?

Worth remembering too that mandeep will be at Bio Europe on 6-8 Nov in Munich.

There’s a commercial momentum building here.

The last time I don’t recall getting an email from the PR group to join a discussion even though I had registered. Don’t know if I will this time.

And her locus is Glycans and avidimab according to her LinkedIn page.

So are we expecting at least 3 RNS’s in the next 10 days?

The good Dr Sehmi is on LinkedIn and even took the time last week to provide me with the link to Lindy’s presentation. Why not communicate directly?

Needless to say these need RNs’d tomorrow alongside a non technical translation with the other promised info on the negotiations.

You can reply directly from the article to sclp on a dedicated form.

Every little helps in helping to spread the word. Although we are on a run up to the end of year and the AGM.

Do you think this is when more new will be released?

Isn’t that the market makers stocking up for the next day? When else have they taken so many on board?

Sad to hear that he has contracted this terrible disease. Looks like he’s going to have surgery first as his movement will be restricted afterwards.

Maybe he could be informed of the expected scib1+ trial?

Hi TF and Cleaner

It’s great to think about the magic meeting of Harries and Durrant. You’ve got to look at their behavioural

Profiles and Harries is a conserver/ holder which means she is strongly risk averse and evidence based. Great for the role she is in. LD is a bit more progressive but evidence based too. However don’t expect anything from Harries as she’s a civil servant where risk is not commercial but political. I wish it was different but this needs a commercial risk taker like Dame Kate Bingham who understands the technology. It’s one of the few things Dom Cummings got right, getting the covid vaccine development out of the hands of DHSC.

Unless we have a commercial escalator for the Porton Down work then it will remain academic.

Meanwhile a warm welcome to all new shareholders here recently. I hope you start to understand the technologies and gain substantially from the LTH commitments.

Right guys,

In all the stuff about commercialisation and Lindy’s options, have you considered when the new chair will be offered options? Interesting?

Anyway what date in sept is this AACR conference?

Hi TF

This is getting past a joke now. Lindy said at the AGM that she would communicate progress on the Modi1 trial but then said she’d await final results before shouting from the rooftops. The latest RNS misses so much info which needs clarification urgently. Fragmented info leads to doubt and uncertainty which after 10 years is testing my patience. I am sure that I’m not alone.

Is it about time to start putting forward a question for the AGM?

Hi guys,

So why at 22.50 tonight should scancell limited like my LinkedIn entry saying? Is this a hint about tomorrow or am I forever an optimist?

We’re all awaiting the latest results of the ModiFY trial which has started well. Very few firms are focusing on stimulating CD4+ helper cells to attack diseases. We are only just starting to understand the new applications of this promising technology.